cervical cancer vaccine News
Most Popular cervical cancer vaccine Story
Cervarix more effective in girls aged 10-14
A new study indicates that GlaxoSmithKline's cervical cancer vaccine Cervarix appears to have a heightened response among girls aged 10 to 14. Researchers say this could mean that younger girls who are vaccinated may have a lower need for booster shots later in life. Cervarix has been shown to target two viruses that account for 70 percent of all cases of cervical cancer.
- read this report from the Independent for more
Latest Headlines
- February 24, 2011
- January 17, 2007
- October 25, 2006
- April 5, 2006
- February 6, 2006
- December 18, 2005
- December 4, 2005
- October 9, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
